The CCT6A paradigm: biomarker potential and therapeutic challenges in oncology and beyond.

Chaperonin Containing TCP1 Subunit 6A (CCT6A), a structurally conserved core subunit of the eukaryotic CCT/TRiC complex, orchestrates ATP-dependent protein folding, cytoskeletal dynamics, and stress-responsive adaptation, reflecting its indispensable role in cellular homeostasis. Emerging evidence highlights CCT6A as a multifaceted oncogenic driver across diverse malignancies (such as colorectal cancer and hepatocellular carcinoma), through metabolic reprogramming, stabilization of oncoproteins, and immunosuppression. Its overexpression correlates with aggressive phenotypes, therapeutic resistance, and poor prognosis, positioning it as a robust diagnostic and prognostic biomarker. Beyond oncology, CCT6A also contributes to autoimmune diseases, pulmonary fibrosis, and acute kidney injury. Despite its therapeutic potential, key challenges include unresolved context-dependent signaling mechanisms, absence of subunit-specific inhibitors, and the need to reconcile CCT6A targeting with preservation of CCT complex functionality. This review delineates CCT6A's multifunctional roles in oncogenesis and immune-metabolic dysregulation, critically evaluates its biomarker potential, and proposes targeted therapeutic frameworks to refine precision medicine paradigms across diverse disease landscapes.